BIO-TECHNE price to free cash flow TECH

Market value divided by free cash flow over the last twelve months, since 2011.

Today, Oct 23, 2026: 43.2×
10-year median: 46.2×
Against its 10-year history: 37th; percentile: 0 is its lowest day, 100 its highest
10-year range: 25.1× to 95.8×
Peer median: 21.8×

BIO-TECHNE's price to free cash flow is 43.2× as of Oct 23, 2026.

That is below its ten-year median of 46.2×, close to the middle of its last ten years.

Over that time it ranged from 25.1× in May 2026 to 95.8× in Feb 2021.

The median for 10 biotech stocks of a similar size is 21.8×.

Price to free cash flow over time

median 46.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	43.2×	25.1×	47.8×
2025	41.2×	29.9×	50.0×
2024	47.3×	43.3×	53.9×
2023	56.6×	42.2×	60.5×
2022	45.7×	39.6×	56.8×
2021	68.9×	60.7×	95.8×
2020	79.9×	38.9×	80.9×
2019	55.1×	37.6×	56.1×
2018	36.9×	35.8×	44.4×
2017	41.4×	28.7×	41.4×
2016	30.6×	26.9×	34.6×
2015	29.3×	26.7×	32.5×
2014	28.1×	26.6×	34.2×
2013	33.7×	19.8×	33.7×
2012	22.1×	19.3×	23.3×
2011	19.8×	18.1×	21.8×

Against its peers

Companies in Biotechnology nearest BIO-TECHNE's size, closest first, today.

Company	Price to free cash flow
TECHBIO-TECHNE	43.2×
RGENRepligen	89.2×
KRYSKrystal Biotech	35.8×
HALOHalozyme Therapeutics	17.7×
NBIXNeurocrine Biosciences	16.7×
EXELExelixis	13.6×
INCYIncyte	12.2×
UTHRUnited Therapeutics	23.1×
ALNYAlnylam Pharmaceuticals	37.8×
ONCBeOne Medicines	32.3×
ADMAAdma Biologics	20.5×
Peer median	21.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on BIO-TECHNE

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.